NASDAQ:MRNS Marinus Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Marinus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.21 -0.25 (-7.23 %) (As of 09/21/2020 12:00 AM ET) Add Compare Share Today's Range$3.17Now: $3.21▼$3.4550-Day Range$1.68MA: $2.06▼$3.4652-Week Range$1.01Now: $3.21▼$4.07Volume3.09 million shsAverage Volume2.42 million shsMarket Capitalization$392.25 millionP/E RatioN/ADividend YieldN/ABeta2 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors. It is also developing ganaxolone for cyclin-ependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, postpartum depression, refractory status epilepticus, and other indications. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingMarinus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.38, Marinus Pharmaceuticals has a forecasted upside of 98.6% from its current price of $3.21.Amount of Analyst CoverageMarinus Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesMarinus Pharmaceuticals has received 376 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMarinus Pharmaceuticals has received 301 “underperform” votes. (Add your “underperform” vote.)Community SentimentMarinus Pharmaceuticals has received 55.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote “Outperform” if you believe MRNS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRNS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMarinus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMarinus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of Marinus Pharmaceuticals is held by insiders.Percentage Held by Institutions74.45% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($0.74) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marinus Pharmaceuticals is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marinus Pharmaceuticals is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarinus Pharmaceuticals has a P/B Ratio of 4.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.79 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRNS Previous Symbol CUSIPN/A CIK1267813 Webwww.marinuspharma.com Phone484-801-4670Debt Debt-to-Equity RatioN/A Current Ratio11.47 Quick Ratio11.47Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book4.46Profitability EPS (Most Recent Fiscal Year)($0.99) Net Income$-54,120,000.00 Net MarginsN/A Return on Equity-110.95% Return on Assets-74.20%Miscellaneous Employees28 Outstanding Shares122,195,000Market Cap$392.25 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $3.21 -0.25 (-7.23 %) (As of 09/21/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MRNS News and Ratings via Email Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions How has Marinus Pharmaceuticals' stock been impacted by COVID-19? Marinus Pharmaceuticals' stock was trading at $1.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRNS stock has increased by 95.7% and is now trading at $3.21. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Marinus Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Marinus Pharmaceuticals. When is Marinus Pharmaceuticals' next earnings date? Marinus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Marinus Pharmaceuticals. How were Marinus Pharmaceuticals' earnings last quarter? Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.03. View Marinus Pharmaceuticals' earnings history. What price target have analysts set for MRNS? 8 analysts have issued 1-year price objectives for Marinus Pharmaceuticals' stock. Their forecasts range from $4.00 to $9.00. On average, they expect Marinus Pharmaceuticals' stock price to reach $6.38 in the next twelve months. This suggests a possible upside of 98.6% from the stock's current price. View analysts' price targets for Marinus Pharmaceuticals. Are investors shorting Marinus Pharmaceuticals? Marinus Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 14,800,000 shares, an increase of 29.8% from the August 15th total of 11,400,000 shares. Based on an average trading volume of 1,850,000 shares, the short-interest ratio is currently 8.0 days. View Marinus Pharmaceuticals' Short Interest. Who are some of Marinus Pharmaceuticals' key competitors? Some companies that are related to Marinus Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), Amarin (AMRN), Y-mAbs Therapeutics (YMAB), INDIVIOR PLC/S (INVVY), Cytokinetics (CYTK), MacroGenics (MGNX), Mersana Therapeutics (MRSN), ZEALAND PHARMA/S (ZEAL), Ligand Pharmaceuticals (LGND), Dicerna Pharmaceuticals (DRNA), Heron Therapeutics (HRTX), ALX Oncology (ALXO), Intercept Pharmaceuticals (ICPT), Rocket Pharmaceuticals (RCKT) and Epizyme (EPZM). View all competitors. What other stocks do shareholders of Marinus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tanker (NAT), The Gabelli Dividend & Income Trust (GDV), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN), Novavax (NVAX), Realty Income (O), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO) and Micron Technology (MU). Who are Marinus Pharmaceuticals' key executives? Marinus Pharmaceuticals' management team includes the following people: Mr. Edward F. Smith, VP, CFO, Treasurer & Sec. (Age 48)Mr. Christopher Michael Cashman, CEO, Pres & Director (Age 62)Dr. Lorianne K. Masuoka, Chief Medical Officer (Age 58)Dr. Scott Braunstein, Exec. Chairman (Age 56)Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations What is Marinus Pharmaceuticals' stock symbol? Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS." Who are Marinus Pharmaceuticals' major shareholders? Marinus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alyeska Investment Group L.P. (2.30%), Granite Point Capital Management L.P. (1.84%), Jefferies Group LLC (1.66%), FMR LLC (1.09%), FMR LLC (1.09%) and WINTON GROUP Ltd (0.98%). Company insiders that own Marinus Pharmaceuticals stock include Christopher Michael Cashman, Edward F Smith and Scott Braunstein. View institutional ownership trends for Marinus Pharmaceuticals. Which major investors are selling Marinus Pharmaceuticals stock? MRNS stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Asymmetry Capital Management L.P., WINTON GROUP Ltd, and UBS Group AG. View insider buying and selling activity for Marinus Pharmaceuticals. Which major investors are buying Marinus Pharmaceuticals stock? MRNS stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, Monashee Investment Management LLC, Alyeska Investment Group L.P., Granite Point Capital Management L.P., Goldman Sachs Group Inc., California Public Employees Retirement System, and Jacobs Levy Equity Management Inc.. View insider buying and selling activity for Marinus Pharmaceuticals. How do I buy shares of Marinus Pharmaceuticals? Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Marinus Pharmaceuticals' stock price today? One share of MRNS stock can currently be purchased for approximately $3.21. How big of a company is Marinus Pharmaceuticals? Marinus Pharmaceuticals has a market capitalization of $392.25 million. The biopharmaceutical company earns $-54,120,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Marinus Pharmaceuticals employs 28 workers across the globe. What is Marinus Pharmaceuticals' official website? The official website for Marinus Pharmaceuticals is www.marinuspharma.com. How can I contact Marinus Pharmaceuticals? Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
